These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 34581022)
1. Impact of conversion surgery on survival in locally advanced pancreatic cancer patients treated with FOLFIRINOX chemotherapy. Lee M; Kang JS; Kim H; Kwon W; Lee SH; Ryu JK; Kim YT; Oh DY; Chie EK; Jang JY J Hepatobiliary Pancreat Sci; 2023 Jan; 30(1):111-121. PubMed ID: 34581022 [TBL] [Abstract][Full Text] [Related]
2. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial. Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V; Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442 [TBL] [Abstract][Full Text] [Related]
3. Association of Modified-FOLFIRINOX-Regimen-Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cancer in Chinese Population. Li X; Guo C; Li Q; Wei S; Zhang Q; Chen Y; Shen Y; Ma T; Li G; Gao S; Que R; Lou J; Yu R; Yuan Y; Wei Q; Huang P; Liang T; Bai X Oncologist; 2019 Mar; 24(3):301-e93. PubMed ID: 30459238 [TBL] [Abstract][Full Text] [Related]
4. Meta-analysis of FOLFIRINOX-based neoadjuvant therapy for locally advanced pancreatic cancer. Chen Z; Lv Y; Li H; Diao R; Zhou J; Yu T Medicine (Baltimore); 2021 Jan; 100(3):e24068. PubMed ID: 33546009 [TBL] [Abstract][Full Text] [Related]
5. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. Hosein PJ; Macintyre J; Kawamura C; Maldonado JC; Ernani V; Loaiza-Bonilla A; Narayanan G; Ribeiro A; Portelance L; Merchan JR; Levi JU; Rocha-Lima CM BMC Cancer; 2012 May; 12():199. PubMed ID: 22642850 [TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis. Barenboim A; Lahat G; Geva R; Nachmany I; Nakache R; Goykhman Y; Brazowski E; Rosen G; Isakov O; Wolf I; Klausner JM; Lubezky N Eur J Surg Oncol; 2018 Oct; 44(10):1619-1623. PubMed ID: 30146251 [TBL] [Abstract][Full Text] [Related]
7. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX. Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344 [TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes of FOLFIRINOX in locally advanced pancreatic cancer: A single center experience. Lee J; Lee JC; Gromski MA; Kim HW; Kim J; Kim J; Hwang JH Medicine (Baltimore); 2018 Dec; 97(50):e13592. PubMed ID: 30558029 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment. van Roessel S; van Veldhuisen E; Klompmaker S; Janssen QP; Abu Hilal M; Alseidi A; Balduzzi A; Balzano G; Bassi C; Berrevoet F; Bonds M; Busch OR; Butturini G; Del Chiaro M; Conlon KC; Falconi M; Frigerio I; Fusai GK; Gagnière J; Griffin O; Hackert T; Halimi A; Klaiber U; Labori KJ; Malleo G; Marino MV; Mortensen MB; Nikov A; Lesurtel M; Keck T; Kleeff J; Pandé R; Pfeiffer P; Pietrasz D; Roberts KJ; Sa Cunha A; Salvia R; Strobel O; Tarvainen T; Bossuyt PM; van Laarhoven HWM; Wilmink JW; Groot Koerkamp B; Besselink MG; JAMA Oncol; 2020 Nov; 6(11):1733-1740. PubMed ID: 32910170 [TBL] [Abstract][Full Text] [Related]
10. Survival Benefit Associated With Resection of Locally Advanced Pancreatic Cancer After Upfront FOLFIRINOX Versus FOLFIRINOX Only: Multicenter Propensity Score-matched Analysis. Brada LJH; Daamen LA; Magermans LG; Walma MS; Latifi D; van Dam RM; de Hingh IH; Liem MSL; de Meijer VE; Patijn GA; Festen S; Stommel MWJ; Bosscha K; Polée MB; Nio YC; Wessels FJ; de Vries JJJ; van Lienden KP; Bruijnen RC; Busch OR; Koerkamp BG; van Eijck C; Molenaar QI; Wilmink HJW; van Santvoort HC; Besselink MG; Ann Surg; 2021 Nov; 274(5):729-735. PubMed ID: 34334641 [TBL] [Abstract][Full Text] [Related]
11. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. Perri G; Prakash L; Qiao W; Varadhachary GR; Wolff R; Fogelman D; Overman M; Pant S; Javle M; Koay EJ; Herman J; Kim M; Ikoma N; Tzeng CW; Lee JE; Katz MHG JAMA Surg; 2020 Sep; 155(9):832-839. PubMed ID: 32667641 [TBL] [Abstract][Full Text] [Related]
12. Patient-tailored FOLFIRINOX as first line treatment of patients with advanced pancreatic adenocarcinoma. Ulusakarya A; Teyar N; Karaboué A; Haydar M; Krimi S; Biondani P; Gumus Y; Chebib A; Almohamad W; Morère JF Medicine (Baltimore); 2019 Apr; 98(16):e15341. PubMed ID: 31008993 [TBL] [Abstract][Full Text] [Related]
13. Predicting overall survival and resection in patients with locally advanced pancreatic cancer treated with FOLFIRINOX: Development and internal validation of two nomograms. Brada LJH; Walma MS; Daamen LA; van Roessel S; van Dam RM; de Hingh IH; Liem MLS; de Meijer VE; Patijn GA; Festen S; Stommel MWJ; Bosscha K; Polée MB; Yung Nio C; Wessels FJ; de Vries JJJ; van Lienden KP; Bruijnen RC; Los M; Mohammad NH; Wilmink HW; Busch OR; Besselink MG; Quintus Molenaar I; van Santvoort HC; J Surg Oncol; 2021 Sep; 124(4):589-597. PubMed ID: 34115379 [TBL] [Abstract][Full Text] [Related]
14. Induction Chemotherapy with FOLFIRINOX for Locally Advanced Pancreatic Cancer: A Simple Scoring System to Predict Effect and Prognosis. Tanaka M; Heckler M; Mihaljevic AL; Ei S; Klaiber U; Heger U; Büchler MW; Hackert T Ann Surg Oncol; 2023 Apr; 30(4):2401-2408. PubMed ID: 36153440 [TBL] [Abstract][Full Text] [Related]
15. Borderline or locally advanced pancreatic adenocarcinoma: A single center experience on the FOLFIRINOX induction regimen. Garnier J; Ewald J; Marchese U; Gilabert M; Moureau-Zabotto L; Giovannini M; Poizat F; Delpero JR; Turrini O Eur J Surg Oncol; 2020 Aug; 46(8):1510-1515. PubMed ID: 32146053 [TBL] [Abstract][Full Text] [Related]
16. Initial experience with neoadjuvant FOLFIRINOX as first line therapy for locally advanced pancreatic cancer. Karachaliou GS; Lazarou V; Giannis D; Astras G; Moris D; Petrou A J BUON; 2020; 25(5):2525-2527. PubMed ID: 33277879 [TBL] [Abstract][Full Text] [Related]
17. Role of surgical resection in the era of FOLFIRINOX for advanced pancreatic cancer. Byun Y; Han Y; Kang JS; Choi YJ; Kim H; Kwon W; Kim SW; Oh DY; Lee SH; Ryu JK; Kim YT; Jang JY J Hepatobiliary Pancreat Sci; 2019 Sep; 26(9):416-425. PubMed ID: 31218836 [TBL] [Abstract][Full Text] [Related]
18. Impact of a non-therapeutic laparotomy in patients with locally advanced pancreatic cancer treated with induction (m)FOLFIRINOX: Trans-Atlantic Pancreatic Surgery (TAPS) Consortium study. Theijse RT; Stoop TF; Janssen QP; Prakash LR; Katz MHG; Doppenberg D; Tzeng CD; Wei AC; Zureikat AH; Groot Koerkamp B; Besselink MG Br J Surg; 2024 Mar; 111(3):. PubMed ID: 38456678 [TBL] [Abstract][Full Text] [Related]
19. Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection. Marchegiani G; Todaro V; Boninsegna E; Negrelli R; Sureka B; Bonamini D; Salvia R; Manfredi R; Pozzi Mucelli R; Bassi C Eur Radiol; 2018 Oct; 28(10):4265-4273. PubMed ID: 29679211 [TBL] [Abstract][Full Text] [Related]
20. Added value of intra-operative ultrasound to determine the resectability of locally advanced pancreatic cancer following FOLFIRINOX chemotherapy (IMAGE): a prospective multicenter study. van Veldhuisen E; Walma MS; van Rijssen LB; Busch OR; Bruijnen RCG; van Delden OM; Mohammad NH; de Hingh IH; Yo LS; van Laarhoven HW; van Leeuwen MS; Nio CY; van Santvoort HC; de Vries J; Wessels FJ; Wilmink JW; Molenaar IQ; Besselink MG; van Lienden KP; HPB (Oxford); 2019 Oct; 21(10):1385-1392. PubMed ID: 31010633 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]